China (Mainland)
Epirubicin HCl 56390-09-1 Epirubicin hydrochloride CAS NO.56390-09-1
- Min.Order: 1 Kilogram
- Payment Terms: T/T,Other
- Product Details
Keywords
- Epirubicin HCl
- Epirubicin hydrochloride
- 56390-09-1
Quick Details
- ProName: Epirubicin HCl 56390-09-1 Epirubicin h...
- CasNo: 56390-09-1
- Molecular Formula: C27H30ClNO11
- Appearance: Orange or red crystalline solid
- Application: API
- DeliveryTime: within one week
- PackAge: 25kgs/drum paper-drums and two plastic...
- Port: Shanghai
- ProductionCapacity: 500 Kilogram/Month
- Purity: ≥98.0%
- Storage: Store in tight containers, in a cool d...
- Transportation: Ordinary and safe chemical, suggestion...
- LimitNum: 1 Kilogram
- Related Substances: Meets the requirements
- Residue on Ignition: ≤0.10%
- Heavy Metal: ≤10 ppm
- Valid Period: 2 years when properly stored
Superiority
Shanghai SOYOUNG onsite assessment conducted by Bureau Veritas commissioned at June 2018. Assessed Supplier of Shanghai SOYOUNG is a faithful and professional supplier of health raw materials in pharmacy, food, cosmetic and other fields for many years, with own laboratories and GMP standard factories.
1. 12 years specialized in health products field.
2. GMP/ISO certificated factories and stable supply chain.
3. Quality first, strictly control before shipments.
4. Custom synthesis by more than 20 professional chemists.
5. Small order,free sample and one step service available.
6. Rapid delivery, 1-6 business days from China warehouse.
7. Support 7 days refund money in case delay shipment.
8. Assessment conducted by Bureau Veritas at 2018.
Details
【Product name】Epirubicin hydrochloride
【CAS No.】56390-09-1
【Molecular formula】C27H29NO11
【Molecular Weight】543.52
【Appearance】Orange or red crystalline solid
【Assay】99%(GC)
【Packing】25kg/drum or at customer's request.
【Storage】Tight container, protect from light
A cell-permeable, antitumor antibiotic. A stereoisomer of doxorubicin that exhibits reduced cardiotoxicity. Its antitumor actions are mediated by targeting topoisomerase II.